COENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE

$575M01FY2000RRNIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications & trials

Paper 39414844 Paper 39386517 Paper 38816203 Paper 38741246 Paper 38278947 Paper 38204926 Paper 37978826 Paper 37292813 Paper 37233759 Paper 37226675 Paper 36933679 Paper 36712107 Paper 36650173 Paper 36280384 Paper 35562076 Paper 35453142 Paper 35019976 Paper 34753805 Paper 34637524 Paper 34496463 Paper 34320286 Paper 33707304 Paper 33627633 Paper 33597215 Paper 33479058 Paper 33178459 Paper 33168654 Paper 33106254 Paper 33071178 Paper 33044802 Paper 33002231 Paper 32861645 Paper 32845968 Paper 32541385 Paper 32404950 Paper 32388179 Paper 32310273 Paper 32193296 Paper 32134326 Paper 32128240 Paper 32085906 Paper 32066692 Paper 32064729 Paper 31898874 Paper 31886931 Paper 31780185 Paper 31709648 Paper 31685489 Paper 31505070 Paper 31418516 Paper 31404238 Paper 31393564 Paper 31338998 Paper 31167889 Paper 31131339 Paper 31118516 Paper 31100122 Paper 30967435 Paper 30900413 Paper 30898204 Paper 30817009 Paper 30804324 Paper 30624677 Paper 30455329 Paper 30421851 Paper 30325779 Paper 30283035 Paper 29950175 Paper 29936086 Paper 29758564 Paper 29697830 Paper 29659886 Paper 29601406 Paper 29545462 Paper 29427697 Paper 29424780 Paper 29398050 Paper 29326107 Paper 29246363 Paper 29226174 Paper 29157731 Paper 29086498 Paper 29053861 Paper 29031905 Paper 28940967 Paper 28930079 Paper 28768705 Paper 28695142 Paper 28678345 Paper 28664624 Paper 28593722 Paper 28378429 Paper 28239652 Paper 28152193 Paper 27870507 Paper 27803118 Paper 27797678 Paper 27732336 Paper 27595918 Paper 27549584

Abstract

The protocol will test the hypothesis that chronic treatment of Huntington's disease patients with Co-Enzyme Q10 and Remacemide, alone in combination will slow the progressive functional decline of Huntington's disease (HD). There is no effective therapy for HD, and inherited progressive degenerative disease that results in dementia and death. The investigators enrolled 21 subjects at Massachusetts General Hospital site. Eighteen subjects continue in study with no complications. Three subjects are early drug discontinuation status due to inability to tolerate study medicaitons. One of the three subjects off medication died six months later of carbon monoxide poisoning. The investigators continue to follow the other two subjects off study drug every four months. There have been no changes to the protocol. There has been no interim analysis of study at this time.

View original record on NIH RePORTER →